Buenas tardes, este es un artículo muy interesante en relación a colposcopia y cáncer cervical.
Saludos
Dr. Carlos Erazo
AIDS:
2 January 2011 - Volume 25 - Issue 1 - p 87–94
doi: 10.1097/QAD.0b013e328340fd99
Epidemiology and Social
Omar, Tanviera; Schwartz, Shereeb; Hanrahan, Colleenb; Modisenyane, Tebogoc; Tshabangu, Nkekoc; Golub, Jonathan Ed; McIntyre, James Ac; Gray, Glenda Ec; Mohapi, Leratoc; Martinson, Neil Ac,d
Abstract
Objective: To ascertain progression and regression of cervical dysplasia in HIV-infected women in Soweto.
Design: Prospective cohort.
Methods: Women attending an HIV wellness clinic were offered cervical smears as part of care; smears were assessed using the Bethesda system. Those with high-grade lesions or worse were referred for colposcopy. Progression analyses included women with at least two smears at least 5.5 months apart. Hazard ratios were used to ascertain predictors of progression.
Results: Two thousand, three hundred and twenty-five women had a baseline smear; their median age and CD4 cell count was 32 years and 312 cells/μl, respectively; 17% were taking highly active antiretroviral therapy (HAART); 62, 20 and 14% had normal, low-grade squamous intraepithelial lesions (LSIL) or high-grade squamous intraepithelial lesions (HSIL), respectively. Of those with baseline normal or LSIL smears, 1074 had another smear; progression from normal to LSIL was 9.6/100 person-years (95% CI 8.3–11.1) and progression from normal or LSIL to HSIL was 4.6/100 person-years (95% CI 3.9–5.5). Of 225 women with LSIL at baseline and at least one subsequent smear at least 11.5 months later, 44.0% regressed to normal (21.2/100 person-years (95% CI 17.5–25.7)). Multivariate models suggested increasing risk for progression in women with CD4 cell count below 500 cells/μl and HAART may reduce the risk of progression [adjusted hazard ratio (aHR) 0.72 (0.52–0.99)].
Conclusion: HIV-infected women have high rates of prevalent and incident HSIL and LSIL with relatively low risk of regression to normal from LSIL. HAART appears to protect against progression. Our findings suggest cervical screening intervals should be less than 10 years – irrespective of age in women with CD4 cell counts below 500 cells/μl.
"An estimated 33.3 million people worldwide have the HIV virus that causes AIDS, but the global health community is starting to slow down and even turn the epidemic around, according to the 
A daily dose of an oral antiretroviral drug containing tenofovir plus emtricitabine (brand name Truvada), currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 44% among men who have sex with men (MSM) and transgender women who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial known as the iPrEx study published online November 23 by the New England Journal of Medicine. Even higher rates of effectiveness, up to 73%, were found among study participants who adhered most closely to the daily drug regimen. Participants also received a comprehensive package of prevention services, which included use of condoms, monthly HIV testing, counseling, and management of other sexually transmitted infections. Read the full text of